



University of  
**Salford**  
MANCHESTER

# **Four-Day Week Trial: South Cambridgeshire Council's Key Performance Indicator Evaluation**

**Dr Joshua Pink**

**Prof Daiga Kamerāde**

**Prof Brendan Burchell\***

## RESEARCH TEAM

*To maintain independence from the research participants and policy makers, the analysis of this data was conducted by a group of researchers from the universities of Cambridge and Salford.*

**Joshua Pink** is a Lecturer in Health Economics in the School of Health and Society at the University of Salford. He has worked as a statistician and health economist in both the public and university sectors, conducting evaluations of healthcare and policy interventions. He worked for six years conducting statistical and economic evaluations for the National Centre for Health and Care Excellence, producing guidance for the UK NHS and social care system.

**Daiga Kamerāde** is a Professor of Work and Wellbeing and a Director of the Centre for Research on Inclusive Society at the School of Health and Society at the University of Salford. She is a highly experienced quantitative work, employment and wellbeing researcher. Daiga was part of the team that evaluated one of the largest four-day workweek trials in the world, conducted in the UK, contributing to the global conversation on innovative work arrangements and their implications for employee wellbeing and organisational performance.

**Brendan Burchell\*** is a Professor in the Social Sciences and a Fellow of Magdalene College at the University of Cambridge. His main research interest is the relationship between employment and wellbeing which he has explored using both quantitative and qualitative research methods. For the past ten years he has specialised in the effects of working time reduction on performance and wellbeing. Other ongoing and recent research projects include national four-day week pilots of UK employers and the Scottish government working time reduction trials. He is the founder of the Work Time Reduction Research Network.

*\*Contact for questions and clarifications: [bb101@cam.ac.uk](mailto:bb101@cam.ac.uk)*

### How to cite this report:

Pink, J., Kamerāde, D., Burchell, B. (2024). Four-Day Week Trial: South Cambridgeshire Council's Key Performance Indicator Evaluation. Research Report. University of Salford/University of Cambridge.

## KEY FINDINGS

When evaluating the impact of the trial on outcomes, it is important to compare results during the trial period to those before the trial period, to estimate changes that may have resulted from the introduction of the trial.

For the analysis **adjusting for the impact of the COVID-19 pandemic period**, the following outcome measures were found to be significantly different during the trial period, compared to before the trial period:

- Outcomes that were better during the trial period, compared to before the trial period:
  - CC303: % of calls to the contact centre that are handled (answered)
  - CC305: % of complaints responded to within timescales (all SCDC)
  - FS109: % of undisputed invoices paid in 30 days
  - FS113: Average number of days to process housing benefit and council tax support change events
  - FS117: % staff turnover
  - SH332: % of emergency housing repairs in 24 hours
  - Planning services measure: major planning application decisions (% completed in time)
  - Planning services measure: major planning application decisions (% overturned)
  - Planning services measure: non-major planning application decisions (% completed in time)
  - Planning services measure: non-major planning application decisions (% overturned)
  - Planning services measure: average number of weeks for householder planning application determination
- Outcomes that were worse during the trial period, compared to before the trial period:
  - FS102: % of housing rent collected
  - AH211: average days to re-let all housing stock

For all other outcomes, no statistically significant difference could be found during the trial period, compared to before the trial period. This does not necessarily mean there was no change – instead it means that any changes were not sufficiently large that it was possible to identify them from the general variation in the outcome over time.

For the analysis **not adjusting for the impact of the COVID-19 pandemic period**, the following outcome measures were found to be statistically significantly different during the trial period compared to before the trial period:

- Outcomes that were better during the trial period, compared to before the trial period:
  - CC303: % of calls to the contact centre that are handled (answered)
  - CC305: % of complaints responded to within timescales (all SCDC)
  - FS109: % of undisputed invoices paid in 30 days
  - FS113: Average number of days to process housing benefit and council tax support change events
  - SH332: % of emergency housing repairs in 24 hours
  - Planning services measure: major planning application decisions (% completed in time)
  - Planning services measure: non-major planning application decisions (% completed in time)
  - Planning services measure: non-major planning application decisions (% overturned)

- Planning services measure: average number of weeks for householder planning application determination
- No outcomes were found to be worse during the trial period, compared to before the trial period.

For all other outcomes, no statistically significant difference could be found during the trial period, compared to before the trial period. This does not necessarily mean there was no change – instead it means that any changes were not sufficiently large that it was possible to identify them from the general variation in the outcome over time.

As with all such analyses, it is important to note the analysis alone cannot prove it was the trial that caused any changes identified, and it is necessary to consider other factors that may have changed over the same time period.

## SUMMARY OF COUNCIL PERFORMANCE RELATIVE TO TARGET AND INTERVENTION VALUES DURING THE TRIAL

This section summarises the performance of the council on the included KPIs compared to their targets during the four-day week trial. This summary represents the performance of the council during the trial period but does not indicate whether the trial itself had a positive, negative or neutral effect, as the KPI targets are measures of absolute performance, not measures of change resulting from the trial. Non-KPI planning service performance measures are not included in this summary, due to not having target or intervention values.

Summary Table 1 summarises whether KPIs met their target values and categorises them based on the frequency of target achievement.

**Summary Table 1: KPI performance by target value**

| KPIs meeting the target value in 100% of the time periods during the trial                     | KPIs meeting the target value in 75-99% of the time periods during the trial                | KPIs meeting the target value in 50-74% of the time periods during the trial | KPIs meeting the target value in less than 50% the time periods during the trial |
|--|---|--|--|
| CC305: % of complaints responded to within timescales (all SCDC)                               | CC303: % of calls to the contact centre that are handled (answered)                         | SF786a: Staff sickness days per FTE - Shared Waste Service only              | CC302: % of calls to the contact centre resolved first time                      |
| FS113: Average number of days to process housing benefit and council tax support change events | FS109: % of undisputed invoices paid in 30 days   | SX025: Average land charges search response days                             | CC307: Average call answer time (seconds)  |
| FS117: % staff turnover  | FS112: Average number of days to process new housing benefit and council tax support claims |  | FS102: % of housing rent collected   |
| SH332: % of emergency housing repairs in 24 hours  | FS125: Staff sickness days per FTE - excluding Shared Waste Service                         |  | FS104: % of business rates collected   |
|  | ES408: % bins collected on schedule   |  | FS105: % of council tax collected  |
|  |   |  | AH204: % tenant satisfaction with responsive repairs                             |
|  |   |  | AH211: Average days to re-let all housing stock                                  |
|  |   |  | ES418: % of household waste sent for reuse, recycling and composting             |

Summary Table 2 examines whether KPIs were below the intervention value and categorises them based on the frequency of KPIs being worse than the intervention value.

**Summary Table 2: KPI performance by intervention value**

| <b>KPIs that are never worse than the intervention value</b>                                   | <b>KPIs that are worse than the intervention value in 1-25% of the time periods during the trial</b> | <b>KPIs that are worse than the intervention value in 26-50% of the time periods during the trial</b> | <b>KPIs that are worse than the intervention value in more than 50% of the time periods during the trial</b> |
|--|--|---|--|
| CC303: % of calls to the contact centre that are handled (answered)                            | CC302: % of calls to the contact centre resolved first time  |   | AH211: Average days to re-let all housing stock  |
| CC305: % of complaints responded to within timescales (all SCDC)                               | CC307: Average call answer time (seconds)  |   |  |
| FS102: % of housing rent collected   | FS104: % of business rates collected   |   |  |
| FS109: % of undisputed invoices paid in 30 days  | FS105: % of council tax collected  |   |  |
| FS112: Average number of days to process new housing benefit and council tax support claims    | SX025: Average land charges search response days   |   |  |
| FS113: Average number of days to process housing benefit and council tax support change events | AH204: % tenant satisfaction with responsive repairs   |   |  |
| FS117: % staff turnover  |  |   |  |
| FS125: Staff sickness days per FTE - excluding Shared Waste Service                            |  |   |  |
| SF786a: Staff sickness days per FTE - Shared Waste Service only                                |  |   |  |
| SH332: % of emergency housing repairs in 24 hours  |  |   |  |
| ES408: % bins collected on schedule  |  |   |  |
| ES418: % of household waste sent for reuse, recycling and composting                           |  |   |  |

## Visualisation of KPI performance


Visualisations of KPI performance during the trial period are presented in Summary Figures 1 and 2 on the following pages. Summary Figure 1 displays KPIs with monthly reported data, while Summary Figure 2 presents KPIs with quarterly reported data.

Months (or quarters) are colour coded as follows:

- Green – The target value for the KPI was achieved.
- Amber – The target value for the KPI was not achieved, but the KPI was not worse than the threshold specified for intervention.
- Red – The target value for the KPI was not achieved, and the KPI reached the threshold specified for intervention.

**Summary Figure 1: KPI performance for monthly KPIs**

**Customer contact service performance outcomes**



**Financial performance**



**Planning service performance**



**Housing services performance**




**Waste management performance**





### Summary Figure 1: KPI performance for quarterly KPIs

#### Customer contact service performance outcomes



#### Staffing (staff turnover and days off sick)



#### Housing services performance



## METHODS

### Data

This report focuses on the performance of the council using Key Performance Indicators (KPIs). A separate report evaluates the impact of the trial on the employees themselves, using measures of their wellbeing, job satisfaction and other indicators.

The primary focus of this report is twofold: to show the performance of the council relative to the targets for each of the KPIs during the 15 months (January 2023-March 2024 inclusive) of the four-day week trial, and to investigate whether the performance during the 15 months of the trial was significantly different from the pre-trial data, controlling for seasonality and additionally (in separate analyses) for the exceptional COVID-19 period.

In total, data are available for 24 performance outcome measures, 19 key performance indicators and 5 planning services measures. There are several differences between the data available for different outcome measures. Some outcomes are based on monthly data, and others based on quarterly data, whilst some outcomes just cover performance for that month, and others are cumulative measures for the financial year up until that time point. The full list of outcome measures and their characteristics is given in Table 1.

**Table 1. Key Performance Indicators.**

| <b>Outcome description</b>                                   | <b>KPI code</b> | <b>Time period for data</b> | <b>Data type</b> |
|--|-----------------|-----------------------------|------------------|
| <b>Customer contact service performance outcomes</b>         |                 |                             |                  |
| % of calls to the contact centre resolved first time         | CC302           | Monthly                     | Non-cumulative   |
| % of calls to the contact centre that are handled (answered) | CC303           | Monthly                     | Non-cumulative   |
| % of complaints responded to within timescales (all SCDC)    | CC305           | Quarterly                   | Non-cumulative   |
| Average call answer time (seconds)                           | CC307           | Monthly                     | Non-cumulative   |
| <b>Financial performance</b>                                 |                 |                             |                  |
| % of housing rent collected                                  | FS102           | Monthly                     | Non-cumulative   |
| % of business rates collected                                | FS104           | Monthly                     | Cumulative       |
| % of council tax collected                                   | FS105           | Monthly                     | Cumulative       |
| % of undisputed invoices paid in 30 days                     | FS109           | Monthly                     | Non-cumulative   |

|   |                 |           |                |
|---|-----------------|-----------|----------------|
| Average number of days to process new housing benefit and council tax support claims    | FS112           | Monthly   | Non-cumulative |
| Average number of days to process housing benefit and council tax support change events | FS113           | Monthly   | Non-cumulative |
| <b>Staffing (staff turnover and days off sick)</b>                                      |                 |           |                |
| % staff turnover  | FS117           | Quarterly | Non-cumulative |
| Staff sickness days per FTE - excluding Shared Waste Service                            | FS125           | Quarterly | Non-cumulative |
| Staff sickness days per FTE - Shared Waste Service only                                 | SF786a          | Quarterly | Non-cumulative |
| <b>Planning service performance</b>   |                 |           |                |
| Average land charges search response days   | SX025           | Monthly   | Non-cumulative |
| Major planning application decisions (% in time)  | N/A – Not a KPI | Monthly   | Non-cumulative |
| Major planning application decisions (% overturned)                                     | N/A – Not a KPI | Monthly   | Non-cumulative |
| Non-major planning application decisions (% in time)                                    | N/A – Not a KPI | Monthly   | Non-cumulative |
| Non-major planning application decisions (% overturned)                                 | N/A – Not a KPI | Monthly   | Non-cumulative |
| Average number of weeks for householder planning application determination              | N/A – Not a KPI | Monthly   | Non-cumulative |
| <b>Housing services performance</b>   |                 |           |                |
| % tenant satisfaction with responsive repairs   | AH204           | Quarterly | Non-cumulative |
| Average days to re-let all housing stock  | AH211           | Monthly   | Non-cumulative |
| % of emergency housing repairs in 24 hours  | SH332           | Monthly   | Non-cumulative |
| <b>Waste management performance</b>   |                 |           |                |
| % bins collected on schedule  | ES408           | Monthly   | Non-cumulative |
| % of household waste sent for reuse, recycling and composting                           | ES418           | Monthly   | Cumulative     |

For most outcome measures, data are available from April 2016, and therefore time series begin at that point. However, for some variables, data were either only collected from a later time point, or the way data were collected was changed to make earlier values no longer comparable, and for these outcomes therefore time series start from a later point. Specifically:

- KPI SF125 (staff sickness days per FTE - excluding Shared Waste Service) is only available from March 2019, as before this point the data for the Shared Waste Service were not separated out from the overall organisation.
- Data for 1 of the non-KPI planning service measures (average number of weeks for householder planning application determination) is only available from April 2018 onwards, and data for the other 4 non-KPI planning service measures is only available from January 2020 onwards.

For most outcome measures, the trial began from 1<sup>st</sup> January 2023, and therefore comparisons of trial to non-trial data use this as the cut-off date. However, for some outcome measures, the trial only began at a later time point. Specifically:

- For KPIs ES408 (% bins collected on schedule), ES418 (% of household waste sent for reuse, recycling and composting) and SF786a (staff sickness days per FTE - Shared Waste Service only) the relevant trial only started on 19<sup>th</sup> September 2023, and therefore the data for September 2023 are the first included as part of the trial in the analysis.

Some council KPIs are not included at all in the analysis, and the above table. The KPIs excluded and the reasons for these exclusions are:

- Eight KPIs were only introduced in the 2022/23 or 2023/24 financial year, and therefore it is not possible to compare them to sufficient historical pre-trial data. These are:
  - AH215 (% successful homeless preventions as a proportion of all homeless cases closed)
  - AH230 (Number of households with children leaving bed and breakfast accommodation after longer than six weeks)
  - AH245 (% of SCDC homes with active HHRS Category 1 or 2 damp and mould cases)
  - CC314 (% of public hybrid meetings run without issues causing downtime exceeding five minutes) and
  - ES430 (% of fly tips cleared within 10 working days)
  - ES412 (kgs of black bin waste per household)
  - ES414 (kgs of total waste per household)
  - PN519 (Average time to determine validated householder planning applications) – this outcome is included as a planning service measure, but was not a KPI until 2022/23 so did not have target or intervention thresholds, and therefore is not analysed as a KPI.

- Four KPIs are reported as average two-year performance, rather than for each month, and therefore the pre- and post-trial periods cannot be separated in the way necessary for analysis. These are PN510 (% of major applications determined within 13 weeks or agreed timeline), PN511 (% of non-major applications determined within eight weeks or agreed timeline), PN512 (% of appeals against major planning permissions refusal allowed) and PN513 (% of appeals against non-major planning permission refusal allowed). These KPIs cover the same data as the four non-KPI planning service measures that are included.

## **Analysis**

Up to 4 analyses were conducted for each outcome measure. Not all analyses were applicable to all outcome measures because of the differences between the data described above. Where an analysis is not conducted for a particular outcome, the reason for that exclusion is described in the results section for the relevant outcome.

### **Analysis 1 – KPI status**

For each KPI, the council has defined target and intervention thresholds for the KPI. For each KPI, target, intervention and actual values are presented for each month or quarter (as applicable to the outcome measure), and are colour coded as follows:

- Green – The target value for the KPI is achieved.
- Amber – The target value for the KPI is not achieved, but the KPI is not worse than the threshold specified for intervention.
- Red – The target value for the KPI is not achieved, and the KPI has reached the threshold specified for intervention.

### **Analysis 2 – Time series**

Graphical representations are provided of the historical data over time, both before and during the trial period. These go from the earliest available data up until the end of March 2024. These graphs present data for each time point it was collected (either monthly or quarterly) and are presented as line graphs for data representing just that time period, and bar charts for data presenting cumulative values for that financial year.

Additionally, graphs showing comparisons of year-on-year averages are also presented. That is, the monthly or quarterly data are summarised into a single value for the whole years, and these are presented. This value is the average of the 12 monthly (or 4 quarterly) values for data representing individual time periods, and the value at the end of the financial year for data presenting cumulative values over financial years.

### **Analysis 3 – regression analysis to estimate impact of trial introduction**

A linear regression analysis was conducted to estimate the impact of the introduction of the trial on the outcome, adjusting for any potential seasonality in the outcome (whether performance varies over the course of the financial year). Thus, the two predictors for the

outcome measure included in the regression are the month (or quarter) the data was collected in, and whether the data were collected before or during the trial period.

When looking at the results of the regression analyses, the value in the “trial” row indicates how much lower (if the regression coefficient is negative) or higher (if the regression coefficient is positive) the outcome was during the trial period, compared to before the trial period.

All changes are reported as absolute rather than relative differences. For example, if an outcome is 50% at baseline and the report mentions a 10% decrease in the outcome, this is a change from 50% to 40%, not a change from 50% to 45%.

#### **Analysis 4 – regression analysis to estimate impact of trial introduction, adjusting for the impact of COVID-19**

Analysis 3 does not explicitly account for the impact of COVID-19 on services, as it includes comparing current data against data collected during the COVID-19 pandemic, when it may be expected that performance on some outcomes would be different.

Therefore, a second linear regression analysis was done, including time of year and the timing of the trial as above, but also including a variable for whether the pandemic was ongoing or not. In the absence of a clear definition for the start and end of the pandemic, the period when some form of lockdown restrictions was in operation was used as a proxy for this, and therefore April 2020 to July 2021 was used as the relevant period.

In the same way analysis 3 may underestimate the impact of COVID-19, it is likely that analysis 4 will overestimate the impact during the specific period defined as the COVID-19 period for analysis. There are likely to be residual effects of the pandemic that persist beyond the end of formal lockdown restrictions, and this is not taken into account in the analysis.

When looking at the results of the regression analyses, the values in the “trial” and “COVID-19 period” rows indicated how much lower (if the regression coefficient is negative) or higher (if the regression coefficient is positive) the outcome was during the trial or COVID-19 periods respectively, compared to outside those periods. As in analysis 3, all changes are reported as absolute rather than relative differences.

## RESULTS

### Customer contact service performance outcomes

#### CC302: % of calls to the contact centre resolved first time

Reported as non-cumulative monthly data, with higher values representing better performance.

**Table 2. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 81.04  | 80     | 70           |
| Feb-23 | 77.78  | 80     | 70           |
| Mar-23 | 78.76  | 80     | 70           |
| Apr-23 | 79.45  | 80     | 70           |
| May-23 | 78.12  | 80     | 70           |
| Jun-23 | 80.34  | 80     | 70           |
| Jul-23 | 80.79  | 80     | 70           |
| Aug-23 | 81.93  | 80     | 70           |
| Sep-23 | 79.82  | 80     | 70           |
| Oct-23 | 76.86  | 80     | 70           |
| Nov-23 | 68.93  | 80     | 70           |
| Dec-23 | 76.59  | 80     | 70           |
| Jan-24 | 80.16  | 80     | 70           |
| Feb-24 | 79.46  | 80     | 70           |
| Mar-24 | 83.71  | 80     | 70           |

Over the period of the trial, there has been 1 month (November 2023) where the KPI registered as worse than the intervention level, 8 months where the target was not met but the KPI was not worse than the intervention level, and 6 months where the target was met (Table 2).

- **Analysis 2 – Time series**

According to Figures 1 and 2, there has been fluctuation in the performance on this outcome measure over time, with the worst performing year being 2021/22.

Figure 1. % of calls to the contact centre resolved first time (monthly)





Figure 2. % of calls to the contact centre resolved first time (YoY)





**Table 3. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 80.68                  | 77.33, 84.03            |
| May   | -0.12                  | -4.84, 4.59             |
| June  | -0.87                  | -5.58, 3.85             |
| July  | -1.71                  | -6.43, 3.00             |
| August  | -0.49                  | -5.21, 4.22             |
| September   | -3.68                  | -8.39, 1.04             |
| October   | -3.14                  | -7.86, 1.57             |
| November  | -4.65                  | -9.36, 0.07             |
| December  | -1.62                  | -6.34, 3.09             |
| January   | -1.79                  | -6.51, 2.94             |
| February  | -0.77                  | -5.50, 3.96             |
| March   | 0.80                   | -3.93, 5.53             |
| Trial   | -0.45                  | -3.13, 2.24             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

The analysis in Table 3 found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 4. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 80.95                  | 77.51, 84.39            |
| May  | -0.12                  | -4.85, 4.61             |
| June   | -0.87                  | -5.60, 3.86             |
| July   | -1.71                  | -6.44, 3.02             |
| August   | -0.61                  | -5.36, 4.13             |
| September  | -3.80                  | -8.54, 0.94             |
| October  | -3.27                  | -8.01, 1.48             |
| November   | -4.77                  | <b>-9.51, -0.03*</b>    |
| December   | -1.75                  | -6.49, 3.00             |
| January  | -1.88                  | -6.63, 2.86             |
| February   | -0.87                  | -5.62, 3.88             |
| March  | 0.70                   | -4.05, 5.45             |
| Trial  | -0.63                  | -3.37, 2.10             |
| COVID-19 period  | -0.98                  | -3.65, 1.69             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

The analysis in Table 4 only found one significant result, which is that outcomes in Novembers appear to be worse than the reference category (April). The impact of the introduction of the trial appears to be minimal, and smaller than both the impact of COVID-19, and the level of month-by-month variation.

**CC303: % of calls to the contact centre that are handled (answered)**

Reported as non-cumulative monthly data, with higher values representing better performance.

**Table 5. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 91.02  | 90     | 80           |
| Feb-23 | 91.61  | 90     | 80           |
| Mar-23 | 88.01  | 90     | 80           |
| Apr-23 | 91.88  | 90     | 80           |
| May-23 | 94.73  | 90     | 80           |
| Jun-23 | 90.67  | 90     | 80           |
| Jul-23 | 88.55  | 90     | 80           |
| Aug-23 | 90.37  | 90     | 80           |
| Sep-23 | 94.96  | 90     | 80           |
| Oct-23 | 96.20  | 90     | 80           |
| Nov-23 | 94.99  | 90     | 80           |
| Dec-23 | 97.44  | 90     | 80           |
| Jan-24 | 96.27  | 90     | 80           |
| Feb-24 | 96.13  | 90     | 80           |
| Mar-24 | 94.90  | 90     | 80           |

As can be seen in Table 5, over the period of the trial, there have been 2 months (March 2023 and July 2023) where the KPI target was not met but the KPI was not worse than the intervention level, and 13 months where the target was met.

- **Analysis 2 – Time series**

According to Figures 3 and 4, there has been fluctuation in the performance on this outcome measure over time, with the worst performing year being 2016/17.

Figure 3. % of calls to the contact centre that are handled/answered (monthly)





Figure 4. % of calls to the contact centre that are handled/answered (YoY)



**Table 6. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 82.26                  | 76.75, 87.77            |
| May   | 2.26                   | -5.50, 10.01            |
| June  | 3.41                   | -4.35, 11.70            |
| July  | 1.47                   | -6.28, 9.23             |
| August  | 1.56                   | -6.19, 9.31             |
| September   | 2.65                   | -5.10, 10.41            |
| October   | 6.01                   | -1.74, 13.76            |
| November  | 7.81                   | <b>0.06, 15.56*</b>     |
| December  | 10.26                  | <b>2.51, 18.01*</b>     |
| January   | 3.93                   | -3.85, 11.70            |
| February  | 5.22                   | -2.55, 12.99            |
| March   | 1.00                   | -6.79, 8.77             |
| Trial   | 7.21                   | <b>2.80, 11.62*</b>     |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

The analysis presented in Table 6 found that outcomes in Novembers and Decembers were significantly better than the reference category (April), and that there was a significant improvement in the trial period, compared to before the trial was introduced. The percentage of calls that were handled was approximately 7% higher during the trial, compared to before.

**Table 7. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 82.30                  | 76.63, 87.98            |
| May  | 2.26                   | -5.54, 10.06            |
| June   | 3.41                   | -4.39, 11.21            |
| July   | 1.47                   | -6.33, 9.27             |
| August   | 1.54                   | -6.28, 9.36             |
| September  | 2.63                   | -5.19, 10.45            |
| October  | 5.99                   | -1.83, 13.81            |
| November   | 7.79                   | -0.03, 15.61            |
| December   | 10.24                  | <b>2.42, 18.06*</b>     |
| January  | 3.91                   | -3.92, 11.74            |
| February   | 5.21                   | -2.63, 13.04            |
| March  | 0.99                   | -6.85, 8.82             |
| Trial  | 7.18                   | <b>2.66, 11.69*</b>     |
| COVID-19 period  | -0.17                  | -4.57, 4.24             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 7, the analysis found that outcomes in Decembers were significantly better than the reference category (April), and that there was a significant improvement in the trial period, compared to before the trial was introduced. The percentage of calls that were handled was approximately 7% higher during the trial, compared to before.

**CC305: % of complaints responded to within timescales (all SCDC)**

Reported as non-cumulative quarterly data, with higher values representing better performance.

**Table 8. Analysis 1 – KPI status**

| KPIs      | Actual | Target | Intervention |
|-----------|--------|--------|--------------|
| Q4, 22/23 | 89.74  | 80     | 70           |
| Q1, 23/24 | 85.54  | 80     | 70           |
| Q2, 23/24 | 85.11  | 80     | 70           |
| Q3, 23/24 | 83.15  | 80     | 70           |
| Q4, 23/24 | 88.54  | 80     | 70           |

According to Table 8, over the period of the trial, the KPI was met for all quarters.

- **Analysis 2 – Time series**

As can be seen in Figures 5 and 6, there has been fluctuation in the performance on this outcome measure over time, with the two most recent financial years (2022/23 and 2023/24) showing the best levels of performance.

Figure 5. % of formal complaints resolved within timescale (quarterly)





Figure 6. % of formal complaints resolved within timescale (YoY)



**Table 9. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 68.88                  | 61.62, 76.15            |
| Quarter 2              | -2.16                  | -12.28, 7.96            |
| Quarter 3              | -0.44                  | -10.56, 9.68            |
| Quarter 4              | 6.60                   | -3.59, 16.80            |
| Trial                  | 15.41                  | <b>5.45, 25.38*</b>     |

<sup>†</sup>Quarter 1 of the financial year, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis in Table 9 found no evidence of any statistically significant effects by quarter of the year but did find a significant improvement in the trial period, compared to before the trial was introduced. The percentage of formal complaints that were resolved within the correct timescale was approximately 15% higher during the trial, compared to before.

**Table 10. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 69.58                  | 62.14, 77.02            |
| Quarter 2              | -1.57                  | -11.81, 8.66            |
| Quarter 3              | -0.44                  | -10.59, 9.72            |
| Quarter 4              | 6.71                   | -3.52, 16.95            |
| Trial                  | 14.55                  | <b>4.38, 24.72*</b>     |
| COVID-19 period        | -4.71                  | -14.88, 5.46            |

<sup>†</sup>Quarter 1 of the financial year, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis in Table 10 found no evidence of any statistically significant effects by quarter of the year, or during the COVID-19 period. However, it did find a significant improvement in the trial period, compared to before the trial was introduced. The percentage of formal complaints that were resolved within the correct timescale was approximately 15% higher during the trial, compared to before.

### **CC307: Average call answer time (seconds)**

Reported as non-cumulative monthly data, with lower values representing better performance.

**Table 11. Analysis 1 – KPI status**

| <b>KPIs</b>   | <b>Actual</b> | <b>Target</b> | <b>Intervention</b> |
|---------------|---------------|---------------|---------------------|
| <b>Jan-23</b> | 139           | 100           | 180                 |
| <b>Feb-23</b> | 141           | 100           | 180                 |
| <b>Mar-23</b> | 178           | 100           | 180                 |
| <b>Apr-23</b> | 128           | 100           | 180                 |
| <b>May-23</b> | 133           | 100           | 180                 |
| <b>Jun-23</b> | 157           | 100           | 180                 |
| <b>Jul-23</b> | 184           | 100           | 180                 |
| <b>Aug-23</b> | 163           | 100           | 180                 |
| <b>Sep-23</b> | 78            | 100           | 180                 |
| <b>Oct-23</b> | 70            | 100           | 180                 |
| <b>Nov-23</b> | 87            | 100           | 180                 |
| <b>Dec-23</b> | 30            | 100           | 180                 |
| <b>Jan-24</b> | 51            | 100           | 180                 |
| <b>Feb-24</b> | 55            | 100           | 180                 |
| <b>Mar-24</b> | 80            | 100           | 180                 |

As can be seen in Table 11, over the period of the trial, there has been 1 month (July 2023) where the KPI registered as worse than the intervention level, 7 months where the target was not met but the KPI was not worse than the intervention level, and 7 months when the target was met.

- **Analysis 2 – Time series**

As Figures 7 and 8 indicate, there has been major fluctuation in the performance on this outcome measure over time, with the worst performing years being 2016/17 and 2019/20.



Figure 7. Average call answer time (seconds) (monthly)





Figure 8. Average call answer time (seconds) (YoY)



**Table 12. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 214.14                 | 144.01, 284.57          |
| May   | -38.10                 | -136.78, 60.59          |
| June  | -40.50                 | -139.18, 58.18          |
| July  | -25.67                 | -124.35, 73.01          |
| August  | -21.74                 | -120.43, 76.94          |
| September   | -38.39                 | -137.07, 60.29          |
| October   | -79.37                 | -178.05, 19.32          |
| November  | -99.28                 | <b>-197.96, -0.60*</b>  |
| December  | -139.15                | <b>-237.83, -40.47*</b> |
| January   | -57.38                 | -156.31, 41.54          |
| February  | -67.68                 | -166.61, 31.24          |
| March   | -12.69                 | -111.62, 86.23          |
| Trial   | -52.03                 | -108.13, 4.08           |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

The analysis presented in Table 12 found two significant results, which are that outcomes in Novembers and Decembers appear to be better than the reference category (April). There is no evidence of a statistically significant impact from the introduction of the trial.

**Table 13. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 205.69                 | 134.00, 277.38          |
| May  | -38.10                 | -136.67, 60.48          |
| June   | -40.50                 | -139.07, 58.07          |
| July   | -25.67                 | -124.24, 72.90          |
| August   | -17.89                 | -116.70, 80.83          |
| September  | -34.54                 | -133.35, 64.28          |
| October  | -75.51                 | -174.32, 23.31          |
| November   | -95.42                 | -194.24, 3.39           |
| December   | -135.30                | <b>-234.11, -36.48*</b> |
| January  | -54.27                 | -153.25, 44.71          |
| February   | -64.57                 | -163.55, 34.41          |
| March  | -9.58                  | -108.56, 89.40          |
| Trial  | -46.11                 | -103.16, 10.94          |
| COVID-19 period  | 30.85                  | -24.81, 86.51           |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 13, the analysis only found 1 significant result, which is that outcomes in Decembers appear to be better than the reference category (April). There is no evidence of a statistically significant impact from either the COVID-19 period, or the introduction of the trial.

## Financial performance

### FS102: % of housing rent collected

Reported as non-cumulative monthly data based on the total expected to be collected by the end of financial year, with higher values representing better performance. Despite the fact target and intervention values increase as the year progresses, this is a non-cumulative dataset, with those increases during the year reflecting the council’s historical experience of rent collection patterns.

**Table 14. Analysis 1 – KPI status**



| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 97.66  | 97.3   | 95.35        |
| Feb-23 | 97.79  | 97.9   | 95.94        |
| Mar-23 | 97.96  | 98     | 96           |
| Apr-23 | 82.99  | 82.6   | 80.95        |
| May-23 | 89.64  | 89.5   | 87.71        |
| Jun-23 | 93.22  | 92.8   | 90.94        |
| Jul-23 | 94.78  | 95.4   | 93.49        |
| Aug-23 | 95.83  | 96     | 94.08        |
| Sep-23 | 96.29  | 97.1   | 95.16        |
| Oct-23 | 96.69  | 97.2   | 95.26        |
| Nov-23 | 97.09  | 97.3   | 95.35        |
| Dec-23 | 97.01  | 97.7   | 95.75        |
| Jan-24 | 97.69  | 97.3   | 95.35        |
| Feb-24 | 97.92  | 97.9   | 95.94        |
| Mar-24 | 97.92  | 98     | 96           |

Table 14 indicates that over the period of the trial, there were 9 months where the target was not met but the KPI was not worse than the intervention level, and 6 months when the target was met.

- **Analysis 2 – Time series**

The within year pattern is relatively consistent over time (see Figures 9 and 10). However, the end of year rent collection percentage was below the target at the end of 2020/21 and

has not met the target level at the end of subsequent financial years. Data for this KPI are not available for December 2020.



**Table 15. Analysis 3 – Regression analysis**

| <b>Variable</b>        | <b>Regression coefficient</b> | <b>95% confidence interval</b> |
|------------------------|-------------------------------|--------------------------------|
| Intercept <sup>†</sup> | 83.23                         | 82.37, 84.10                   |
| May                    | 7.35                          | <b>6.13, 8.56*</b>             |
| June                   | 10.45                         | <b>9.234, 11.67*</b>           |
| July                   | 11.99                         | <b>10.77, 13.20*</b>           |
| August                 | 12.78                         | <b>11.56, 13.99*</b>           |
| September              | 13.45                         | <b>12.24, 14.67*</b>           |
| October                | 14.00                         | <b>12.79, 15.21*</b>           |
| November               | 14.31                         | <b>13.09, 15.52*</b>           |
| December               | 14.44                         | <b>13.19, 15.70*</b>           |
| January                | 14.76                         | <b>13.55, 15.98*</b>           |
| February               | 14.97                         | <b>13.76, 16.19*</b>           |
| March                  | 15.10                         | <b>13.88, 16.31*</b>           |
| Trial                  | -0.43                         | -1.12, 0.26                    |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

There is a clear pattern in the data of increases month by month over the financial year (see Table 15), but there is no evidence of a significant impact of the trial on the outcome.

**Table 16. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| <b>Variable</b>        | <b>Regression coefficient</b> | <b>95% confidence interval</b> |
|------------------------|-------------------------------|--------------------------------|
| Intercept <sup>†</sup> | 83.69                         | 82.93, 84.45                   |
| May                    | 7.35                          | <b>6.30, 8.39*</b>             |
| June                   | 10.45                         | <b>9.41, 11.50*</b>            |
| July                   | 11.99                         | <b>10.94, 13.03*</b>           |
| August                 | 12.57                         | <b>11.52, 13.61*</b>           |
| September              | 13.24                         | <b>12.20, 14.29*</b>           |
| October                | 13.79                         | <b>12.74, 14.84*</b>           |
| November               | 14.10                         | <b>13.05, 15.14*</b>           |
| December               | 14.03                         | <b>12.94, 15.12*</b>           |
| January                | 14.59                         | <b>13.54, 15.64*</b>           |
| February               | 14.80                         | <b>13.75, 15.85*</b>           |
| March                  | 14.93                         | <b>13.88, 15.97*</b>           |
| Trial                  | -0.74                         | <b>-1.34, -0.13*</b>           |
| COVID-19 period        | -1.67                         | <b>-2.28, -1.06*</b>           |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

There is a clear pattern of increases month by month over the financial year (see Table 16). There is also evidence that both the trial and COVID-19 periods were worse than the long-

term average, with the percentage of housing rent collected 1.7 percentage points lower than the long-term average during the COVID-19 period, and 0.7 percentage points lower than the long-term average during the trial.

#### **FS104: % of business rates collected**

Reported as cumulative monthly data based on the total expected to be collected by the end of the financial year, with higher values representing better performance.

Unlike for most other KPIs, the focus of this analysis is on the end of financial year performance, rather than on month-by-month performance, as the council’s key target for this cumulative measure is judged at year-end. Therefore, although the same analyses are undertaken as for other measures, the interpretation is slightly different.



**Table 17. Analysis 1 – KPI status**

| <b>KPIs</b>   | <b>Actual</b> | <b>Target</b> | <b>Intervention</b> |
|---------------|---------------|---------------|---------------------|
| <b>Jan-23</b> | 93.8          | 95.5          | 93.59               |
| <b>Feb-23</b> | 97.7          | 98.4          | 96.43               |
| <b>Mar-23</b> | 98.2          | 99.1          | 97                  |
| <b>Apr-23</b> | 13.1          | 13            | 12.74               |
| <b>May-23</b> | 22.0          | 22.69         | 22.24               |
| <b>Jun-23</b> | 32.3          | 31.73         | 31.1                |
| <b>Jul-23</b> | 42.1          | 40.98         | 40.16               |
| <b>Aug-23</b> | 51.7          | 50.2          | 49.2                |
| <b>Sep-23</b> | 64.8          | 59.78         | 58.58               |
| <b>Oct-23</b> | 69.0          | 68.66         | 67.29               |
| <b>Nov-23</b> | 77.5          | 77.85         | 76.29               |
| <b>Dec-23</b> | 84.6          | 86.3          | 84.57               |
| <b>Jan-24</b> | 93.1          | 95.5          | 93.59               |
| <b>Feb-24</b> | 95.7          | 98.4          | 96.43               |
| <b>Mar-24</b> | 98.9          | 99.1          | 97                  |

Over the period of the trial, there has been 3 months (May 2023, January 2024 and February 2024) where the KPI registered as worse than the intervention level, 6 months where the target was not met but the KPI was not worse than the intervention level, and 6 months when the target was met (Table 17). The KPI was below the target but not worse than the intervention level at both year-ends included in the sample (March 2023 and March 2024).

- **Analysis 2 – Time series**

According to Figures 11 and 12, there has been fluctuation in the year-end performance on this outcome measure over time, with the worst performing years being 2020/21 and 2022/23.



**Table 18. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 13.53                  | 12.63, 14.44            |
| May   | 9.38                   | <b>8.10, 10.65*</b>     |
| June  | 19.24                  | <b>17.96, 20.51*</b>    |
| July  | 28.16                  | <b>26.89, 29.44*</b>    |
| August  | 37.59                  | <b>36.31, 38.86*</b>    |
| September   | 47.19                  | <b>45.91, 48.46*</b>    |
| October   | 55.33                  | <b>54.05, 56.60*</b>    |
| November  | 64.05                  | <b>62.78, 65.32*</b>    |
| December  | 72.55                  | <b>71.28, 73.82*</b>    |
| January   | 81.31                  | <b>80.03, 82.59*</b>    |
| February  | 84.16                  | <b>82.88, 85.44*</b>    |
| March   | 85.54                  | <b>84.26, 86.82*</b>    |
| Trial   | -0.27                  | -0.99, 0.46             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As would be expected from an outcome that is measured cumulatively over the financial year, we can see in Table 18 that there is a clear pattern of increases month by month over the financial year. There is no evidence of a significant impact of the trial on the outcome.

**Table 19. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 14.04                  | 13.27, 14.81            |
| May  | 9.38                   | <b>8.31, 10.44*</b>     |
| June   | 19.24                  | <b>18.18, 20.30*</b>    |
| July   | 28.16                  | <b>27.10, 29.22*</b>    |
| August   | 37.36                  | <b>36.29, 38.42*</b>    |
| September  | 46.96                  | <b>45.89, 48.02*</b>    |
| October  | 55.09                  | <b>54.03, 56.16*</b>    |
| November   | 63.82                  | <b>62.76, 64.88*</b>    |
| December   | 72.32                  | <b>71.26, 73.38*</b>    |
| January  | 81.12                  | <b>80.06, 82.19*</b>    |
| February   | 83.97                  | <b>82.91, 85.04*</b>    |
| March  | 85.35                  | <b>84.29, 86.42*</b>    |
| Trial  | -0.62                  | <b>-1.24, -0.01*</b>    |
| COVID-19 period  | -1.85                  | <b>-2.45, -1.25*</b>    |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |



As can be seen in Table 19, and as would be expected from an outcome that is measured cumulatively over the financial year, there is a clear pattern of increases month by month over the financial year. There is evidence that both the trial and COVID-19 periods were worse than the long-term average, with the percentage of business rates collected 1.9 percentage points lower than the long-term average during the COVID-19 period, and 0.6 percentage points lower than the long-term average during the trial.

The council usually make comparisons for this outcome based on year-end performance than on month-to-month variations. The year-end data for this measure are as follows (data shown in Figure 12):

- End of financial year 2016/17: 99.46%
- End of financial year 2017/18: 99.45%
- End of financial year 2018/19: 99.50%
- End of financial year 2019/20: 99.38%
- End of financial year 2020/21: 98.17%
- End of financial year 2021/22: 99.02%
- End of financial year 2022/23: 98.18%
- End of financial year 2023/24: 98.90%

There are not sufficient end-of-year data points available to conduct a robust statistical analysis. However, with the 2023/24 financial year being the first full year of the trial, there does not appear to be a pattern of worse performance in that year, compared to the recent preceding years.

The conclusion therefore is that although business rate collection was somewhat slower in the earlier months of the financial year during the trial, compared to before the trial, this difference was no longer present at year-end. Therefore, this outcome is not included in the list of outcomes that were worse during the trial, compared to before the trial. It should be noted, however, that were performance to be judged monthly in line with other KPIs, then performance would be judged to be worse for this KPI during the trial period, compared to before the trial period, in the analysis adjusting for the COVID-19 period.

#### **FS105: % of council tax collected**

Reported as cumulative monthly data based on the total expected to be collected by the end of the financial year, with higher values representing better performance.

Unlike for most other KPIs, the focus of this analysis is on the end of financial year performance, rather than on month-by-month performance, as the council's key target for

this cumulative measure is judged at year-end. Therefore, although the same analyses are undertaken as for other measures, the interpretation is slightly different.

**Table 20. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 95.4   | 97.8   | 95.84        |
| Feb-23 | 98.2   | 98.6   | 96.63        |
| Mar-23 | 99.2   | 99.1   | 97.1         |
| Apr-23 | 11.0   | 11     | 10.78        |
| May-23 | 20.7   | 21     | 20.58        |
| Jun-23 | 30.1   | 30     | 29.4         |
| Jul-23 | 39.4   | 39.76  | 38.96        |
| Aug-23 | 49.2   | 48.96  | 47.98        |
| Sep-23 | 58.5   | 58.56  | 57.39        |
| Oct-23 | 67.4   | 67.76  | 66.4         |
| Nov-23 | 76.7   | 77.06  | 75.52        |
| Dec-23 | 85.8   | 86.16  | 84.44        |
| Jan-24 | 95.1   | 95.26  | 93.35        |
| Feb-24 | 97.5   | 97.93  | 95.97        |
| Mar-24 | 99.3   | 99.1   | 97.11        |

As can be seen in Table 20, over the period of the trial, there has been 1 month (January 2023) where the KPI registered as worse than the intervention level, 9 months where the target was not met but KPI was not worse than the intervention level, and 5 months when the target was met.

The KPI met the target at both year-ends included in the sample (March 2023 and March 2024).

- **Analysis 2 – Time series**

According to Figures 13 and 14, with the exception of one financial year (2020/21), the performance on this KPI has been consistently above the target level at the end of each financial year.

Figure 13. % of council tax collected (monthly)





Figure 14. % of council tax collected (YoY)



**Table 21. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 14.36                  | 13.39, 15.34            |
| May                    | 9.39                   | <b>8.02, 10.76*</b>     |
| June                   | 18.59                  | <b>17.22, 19.96*</b>    |
| July                   | 27.85                  | <b>26.348, 29.22*</b>   |
| August                 | 37.10                  | <b>35.73, 38.47*</b>    |
| September              | 46.48                  | <b>45.10, 47.85*</b>    |
| October                | 55.41                  | <b>54.04, 56.78*</b>    |
| November               | 64.63                  | <b>63.25, 66.00*</b>    |
| December               | 73.65                  | <b>72.28, 75.02*</b>    |
| January                | 83.07                  | <b>81.70, 84.45*</b>    |
| February               | 84.64                  | <b>83.26, 86.01*</b>    |
| March                  | 85.42                  | <b>84.05, 86.80*</b>    |
| Trial                  | -2.08                  | <b>-2.86, -1.30*</b>    |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As would be expected from an outcome that is measured cumulatively over the financial year, there is a clear pattern in Table 21 of increases month by month over the financial year. There is evidence that both the trial and COVID-19 periods were worse than the long-term average, with the percentage of council tax collected 2.1 percentage points lower than the long-term average during the trial.

**Table 22. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 14.58                  | 13.60, 15.56            |
| May                    | 9.39                   | <b>8.04, 10.73*</b>     |
| June                   | 18.59                  | <b>17.25, 19.94*</b>    |
| July                   | 27.85                  | <b>26.51, 29.19*</b>    |
| August                 | 37.00                  | <b>35.65, 38.35*</b>    |
| September              | 46.37                  | <b>45.03, 47.72*</b>    |
| October                | 55.31                  | <b>53.96, 56.66*</b>    |
| November               | 64.52                  | <b>63.18, 56.87*</b>    |
| December               | 73.55                  | <b>72.20, 74.90*</b>    |
| January                | 82.99                  | <b>81.65, 84.34*</b>    |
| February               | 84.55                  | <b>83.20, 85.90*</b>    |
| March                  | 85.34                  | <b>83.99, 86.69*</b>    |
| Trial                  | -2.24                  | <b>-3.01, -1.46*</b>    |
| COVID-19 period        | -0.81                  | <b>-1.57, -0.05*</b>    |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As would be expected from an outcome that is measured cumulatively over the financial year, in Table 22 there is a clear pattern of increases month by month over the financial year. There is evidence that both the trial and COVID-19 periods were worse than the long-term average, with the percentage of council tax collected 0.8 percentage points lower than the long-term average during the COVID-19 period, and 2.2 percentage points lower than the long-term average during the trial.

The council usually make comparisons for this outcome based on year-end performance than on month-to-month variations. The year-end data for this measure are as follows (data shown in Figure 14):

- End of financial year 2016/17: 99.40%
- End of financial year 2017/18: 99.34%
- End of financial year 2018/19: 99.37%
- End of financial year 2019/20: 99.26%
- End of financial year 2020/21: 99.05%
- End of financial year 2021/22: 99.14%
- End of financial year 2022/23: 99.23%
- End of financial year 2023/24: 99.30%

There are not sufficient end-of-year data points available to conduct a robust statistical analysis. However, with the 2023/24 financial year being the first full year of the trial, there does not appear to be a pattern of worse performance in that year, compared to the recent preceding years.

The conclusion therefore is that although council tax collection was somewhat slower in the earlier months of the financial year during the trial, compared to before the trial, this difference was no longer present at year-end. Therefore, this outcome is not included in the list of outcomes that were worse during the trial, compared to before the trial. It should be noted, however, that were performance to be judged monthly in line with other KPIs, then performance would be judged to be worse for this KPI during the trial period, compared to before the trial period.

### **FS109: % of undisputed invoices paid in 30 days**

Reported as non-cumulative monthly data, with higher values representing better performance.



**Table 23. Analysis 1 – KPI status**

| <b>KPIs</b>   | <b>Actual</b> | <b>Target</b> | <b>Intervention</b> |
|---------------|---------------|---------------|---------------------|
| <b>Jan-23</b> | 98.74         | 98.5          | 96.5                |
| <b>Feb-23</b> | 98.93         | 98.5          | 96.5                |
| <b>Mar-23</b> | 98.42         | 98.5          | 96.5                |
| <b>Apr-23</b> | 99.56         | 98.5          | 96.5                |
| <b>May-23</b> | 98.86         | 98.5          | 96.5                |
| <b>Jun-23</b> | 99.56         | 98.5          | 96.5                |
| <b>Jul-23</b> | 99.20         | 98.5          | 96.5                |
| <b>Aug-23</b> | 98.64         | 98.5          | 96.5                |
| <b>Sep-23</b> | 98.55         | 98.5          | 96.5                |
| <b>Oct-23</b> | 98.97         | 98.5          | 96.5                |
| <b>Nov-23</b> | 98.96         | 98.5          | 96.5                |
| <b>Dec-23</b> | 99.50         | 98.5          | 96.5                |
| <b>Jan-24</b> | 99.04         | 98.5          | 96.5                |
| <b>Feb-24</b> | 99.17         | 98.5          | 96.5                |
| <b>Mar-24</b> | 99.93         | 98.5          | 96.5                |

As indicated by Table 23, over the period of the trial, there has been 1 month (March 2023) where the KPI target was not met but the KPI was not worse than the intervention level, and 14 months where the target was met.

- **Analysis 2 – Time series**

According to Figure 15 and 16, in 2018/19 and earlier, this KPI was consistently below the target value, whilst since 2019/20 the KPI has consistently been met on average across the financial year.



**Table 24. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 98.01                  | 96.64, 99.37            |
| May                    | -0.02                  | -1.93, 1.90             |
| June                   | -0.67                  | -2.58, 1.25             |
| July                   | -0.31                  | -2.22, 1.61             |
| August                 | -0.33                  | -2.24, 1.59             |
| September              | -0.07                  | -1.99, 1.85             |
| October                | -0.57                  | -2.48, 1.35             |
| November               | -0.65                  | -2.57, 1.27             |
| December               | -0.41                  | -2.33, 1.51             |
| January                | -1.36                  | -3.28, 0.57             |
| February               | -1.19                  | -3.11, 0.73             |
| March                  | -0.16                  | -2.08, 1.76             |
| Trial                  | 1.62                   | <b>0.53, 2.71*</b>      |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 24, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement in the trial period, compared to before the trial was introduced. The percentage of undisputed invoices that were paid in 30 days was approximately 1.6% higher during the trial, compared to before.

**Table 25. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 97.60                  | 96.26, 98.94            |
| May                    | -0.02                  | -1.86, 1.82             |
| June                   | -0.67                  | -2.51, 1.17             |
| July                   | -0.31                  | -2.15, 1.53             |
| August                 | -0.14                  | -1.98, 1.70             |
| September              | 0.12                   | -1.73, 1.96             |
| October                | -0.38                  | -2.22, 1.46             |
| November               | -0.46                  | -2.31, 1.38             |
| December               | -0.22                  | -2.07, 1.62             |
| January                | -1.20                  | -3.05, 0.64             |
| February               | -1.04                  | -2.89, 0.81             |
| March                  | -0.01                  | -1.85, 1.84             |
| Trial                  | 1.91                   | <b>0.84, 2.97*</b>      |
| COVID-19 period        | 1.49                   | <b>0.45, 2.53*</b>      |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level



The analysis presented in Table 25 found no evidence of any statistically significant effects by month of the year but did find significant improvements in both the COVID-19 and trial periods, compared to outside those periods. The percentage of undisputed invoices that were paid in 30 days was approximately 1.5% higher COVID-19 period, compared to the long-term average, and 1.9% higher during the trial, compared to the long-term average.

**FS112: Average number of days to process new housing benefit and council tax support claims**

Reported as non-cumulative monthly data, with lower values representing better performance.

**Table 26. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 6      | 15     | 20           |
| Feb-23 | 10     | 15     | 20           |
| Mar-23 | 14     | 15     | 20           |
| Apr-23 | 19     | 15     | 20           |
| May-23 | 14     | 15     | 20           |
| Jun-23 | 9      | 15     | 20           |
| Jul-23 | 9      | 15     | 20           |
| Aug-23 | 13     | 15     | 20           |
| Sep-23 | 12     | 15     | 20           |
| Oct-23 | 13     | 15     | 20           |
| Nov-23 | 10     | 15     | 20           |
| Dec-23 | 11     | 15     | 20           |
| Jan-24 | 10     | 15     | 20           |
| Feb-24 | 10     | 15     | 20           |
| Mar-24 | 12     | 15     | 20           |

According to Table 26, over the period of the trial, there has been 1 month (April 2023) where the KPI target was not met but the KPI was not worse than the intervention level, and 14 months where the target was met.

- **Analysis 2 – Time series**

As can be seen in Figure 17 and 18, this KPI has been consistently met or exceeded on average over the years where data are available.

Figure 17. Average number of days to process new HB/CTS claims (monthly)





Figure 18. Average number of days to process new HB/CTS claims (YoY)



**Table 27. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 15.84                  | 12.79, 18.89            |
| May   | -1.88                  | -6.16, 2.41             |
| June  | -2.38                  | -6.66, 1.91             |
| July  | -2.25                  | -6.54, 2.04             |
| August  | -2.38                  | -6.66, 1.91             |
| September   | -3.13                  | -7.41, 1.16             |
| October   | -6.88                  | <b>-11.16, -2.59*</b>   |
| November  | -7.00                  | <b>-11.29, -2.71*</b>   |
| December  | -6.25                  | <b>-10.54, -1.96*</b>   |
| January   | -4.41                  | <b>-8.71, -0.11*</b>    |
| February  | -4.78                  | <b>-9.08, -0.48*</b>    |
| March   | -2.03                  | -6.33, 2.27             |
| Trial   | -0.74                  | -3.18, 1.70             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

The analysis presented in Table 27, found five significant results, which are that outcomes from October-February appear to be better than the reference category (April). There is no evidence of a statistically significant impact from the introduction of the trial.

**Table 28. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 15.77                  | 12.63, 18.91            |
| May  | -1.88                  | -6.19, 2.44             |
| June   | -2.38                  | -6.69, 1.94             |
| July   | -2.25                  | -6.56, 2.06             |
| August   | -2.34                  | -6.67, 1.98             |
| September  | -3.09                  | -7.42, 1.23             |
| October  | -6.84                  | <b>-11.17, -2.52*</b>   |
| November   | -6.97                  | <b>-11.29, -2.64*</b>   |
| December   | -6.22                  | <b>-10.54, -1.89*</b>   |
| January  | -4.38                  | <b>-8.71, -0.05*</b>    |
| February   | -4.76                  | <b>-9.09, -0.42*</b>    |
| March  | -2.01                  | -6.34, 2.33             |
| Trial  | -0.69                  | -3.18, 1.81             |
| COVID-19 period  | 0.27                   | -2.17, 2.71             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

In Table 28, the analysis found five significant results, which are that outcomes from October-February appear to be better than the reference category (April). There is no evidence of a statistically significant impact from either the COVID-19 period or the introduction of the trial.

**FS113: Average number of days to process housing benefit and council tax support change events**

Reported as non-cumulative monthly data, with lower values representing better performance.



**Table 29. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 4      | 10     | 15           |
| Feb-23 | 3      | 10     | 15           |
| Mar-23 | 6      | 10     | 15           |
| Apr-23 | 7      | 10     | 15           |
| May-23 | 6      | 10     | 15           |
| Jun-23 | 6      | 10     | 15           |
| Jul-23 | 5      | 10     | 15           |
| Aug-23 | 4      | 10     | 15           |
| Sep-23 | 4      | 10     | 15           |
| Oct-23 | 7      | 10     | 15           |
| Nov-23 | 4      | 10     | 15           |
| Dec-23 | 3      | 10     | 15           |
| Jan-24 | 5      | 10     | 15           |
| Feb-24 | 4      | 10     | 15           |
| Mar-24 | 5      | 10     | 15           |

As can be seen in Table 29, over the period of the trial, the KPI was met for all quarters.

- **Analysis 2 – Time series**

As indicated by Figures 19 and 20, this KPI has been consistently met or exceeded on average over the years where data are available.



**Table 30. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 10.54                  | 8.84, 12.24             |
| May   | -0.75                  | -3.14, 1.64             |
| June  | -1.38                  | -3.77, 1.01             |
| July  | -1.50                  | -3.89, 0.89             |
| August  | -1.13                  | -3.52, 1.27             |
| September   | -1.50                  | -3.89, 0.89             |
| October   | -2.63                  | <b>-5.02, -0.23*</b>    |
| November  | -3.75                  | <b>-6.14, -1.36*</b>    |
| December  | -4.25                  | <b>-6.64, -1.86*</b>    |
| January   | -1.71                  | -4.11, 0.68             |
| February  | -4.96                  | <b>-7.36, -2.57*</b>    |
| March   | -2.71                  | <b>-5.11, -0.32*</b>    |
| Trial   | -3.29                  | <b>-4.65, -1.93*</b>    |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As seen in Table 30, the analysis found six significant results, which are that outcomes from October, November, December, February and March appear to be better than the reference category (April), and there is a statistically significant improvement in the trial period, compared to before the trial was introduced. There is an approximately 3.3 day reduction in the number of days to process a housing benefit or council tax support change during the trial, compared to before.

**Table 31. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 10.44                  | 8.69, 12.19             |
| May  | -0.75                  | -3.15, 1.65             |
| June   | -1.38                  | -3.78, 1.03             |
| July   | -1.38                  | -3.90, 0.90             |
| August   | -1.08                  | -3.49, 1.33             |
| September  | -1.46                  | -3.87, 0.95             |
| October  | -2.58                  | <b>-4.99, -0.17*</b>    |
| November   | -3.71                  | <b>-6.12, 1.30*</b>     |
| December   | -4.21                  | <b>-6.62, -1.80*</b>    |
| January  | -1.68                  | -4.09, 0.73             |
| February   | -4.93                  | <b>-7.34, -2.52*</b>    |
| March  | -2.68                  | <b>-5.09, -0.26*</b>    |
| Trial  | -3.23                  | <b>-4.62, -1.84*</b>    |
| COVID-19 period  | 0.34                   | -1.01, 1.70             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 31, the analysis found six significant results, which are that outcomes from October, November, December, February and March appear to be better than the reference category (April), and there is a statistically significant improvement in the trial period, compared to before the trial was introduced. There is an approximately 3.2 day reduction in the number of days to process a housing benefit or council tax support change during the trial, compared to before.

## Staffing (staff turnover and days off sick)

### FS117: % staff turnover

Reported as non-cumulative quarterly data, with lower values representing better performance.

**Table 32. Analysis 1 – KPI status**

| KPIs      | Actual | Target | Intervention |
|-----------|--------|--------|--------------|
| Q4, 22/23 | 1.66   | 3.25   | 4            |
| Q1, 23/24 | 2.27   | 3.25   | 4            |
| Q2, 23/24 | 1.90   | 3.25   | 4            |
| Q3, 23/24 | 2.04   | 3.25   | 4            |
| Q4, 23/24 | 1.87   | 3.25   | 4            |

As can be seen in Table 32, over the period of the trial, the KPI was met for all quarters.

- **Analysis 2 – Time series**

As indicated by Figure 21 and 22, this KPI has been generally met over the years for which data are available, but voluntary staff turnover was slightly worse than the target in 2016/17 and 2021/22.

Figure 21. Staff turnover (non-cumulative) (monthly)





Figure 22. Staff turnover (non-cumulative) (YoY)





**Table 33. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 3.02                   | 2.36, 3.68              |
| Quarter 2              | 0.22                   | -0.70, 1.13             |
| Quarter 3              | -0.62                  | -1.54, 0.29             |
| Quarter 4              | -0.30                  | -1.22, 0.62             |
| Trial                  | -0.87                  | -1.77, 0.03             |

<sup>†</sup>Quarter 1 of the financial year, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis presented in Table 33 found no evidence of any statistically significant effects, either by quarter or from when the trial was started.

**Table 34. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 3.14                   | 2.50, 3.78              |
| Quarter 2              | 0.32                   | -0.56, 1.20             |
| Quarter 3              | -0.62                  | -1.50, 0.26             |
| Quarter 4              | -0.28                  | -1.16, 0.60             |
| Trial                  | -1.02                  | <b>-1.90, -0.14*</b>    |
| COVID-19 period        | -0.81                  | -1.68, 0.07             |

<sup>†</sup>Quarter 1 of the financial year, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis in Table 34 found no evidence of any statistically significant effects by quarter of the year, or during the COVID-19 period. However, it did find a significant improvement in the trial period, compared to before the trial was introduced. Staff turnover was approximately 1 percentage point lower during the trial, compared to before.

### FS125: Staff sickness days per FTE - excluding Shared Waste Service

Reported as non-cumulative quarterly data, with lower values representing better performance.


**Table 35. Analysis 1 – KPI status**


| KPIs      | Actual | Target | Intervention |
|-----------|--------|--------|--------------|
| Q4, 22/23 | 1.64   | 1.75   | 2.5          |
| Q1, 23/24 | 1.18   | 1.75   | 2.5          |
| Q2, 23/24 | 1.70   | 1.75   | 2.5          |
| Q3, 23/24 | 1.67   | 1.75   | 2.5          |
| Q4, 23/24 | 1.94   | 1.75   | 2.5          |

Over the period of the trial, there has been 1 quarter (January-March 2024) where the KPI target was not met but the KPI was not worse than the intervention level, and 4 quarters when the target was met (see Table 35).

- **Analysis 2 – Time series**

According to Figure 23 and 24, this KPI has generally been met over time, but staff sickness was above the target level in 2019/20, and in September-December 2021.





**Table 36. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 1.30                   | 0.92, 1.69              |
| Quarter 2              | 0.29                   | -0.24, 0.83             |
| Quarter 3              | 0.45                   | -0.08, 0.98             |
| Quarter 4              | 0.39                   | -0.15, 0.93             |
| Trial                  | 0.02                   | -0.43, 0.46             |

<sup>†</sup>Quarter 1 of the financial year, outside of the trial period, is used as the reference category in the analysis

\*Result is statistically significant at the 95% level

The analysis in Table 36 found no evidence of any statistically significant effects, either by quarter or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of quarter-by-quarter variation.

**Table 37. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 1.45                   | 1.12, 1.77              |
| Quarter 2              | 0.40                   | -0.03, 0.84             |
| Quarter 3              | 0.45                   | <b>0.02, 0.88*</b>      |
| Quarter 4              | 0.43                   | -0.00, 0.86             |
| Trial                  | -0.17                  | -0.54, 0.21             |
| COVID-19 period        | -0.55                  | <b>-0.92, -0.17*</b>    |

<sup>†</sup>Quarter 1 of the financial year, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis in Table 37 found that staff sickness in quarter 3 of the financial year was higher on average than the reference category (quarter 1), and that staff sickness during the COVID-19 period was lower than outside of it. The impact of the introduction of the trial appears to be minimal, and smaller than both the impact of COVID-19, and the level of quarter-by-quarter variation.

#### **SF786a: Staff sickness days per FTE - Shared Waste Service only**

Reported as non-cumulative quarterly data, with lower values representing better performance.

**Table 38. Analysis 1 – KPI status**

| KPIs      | Actual | Target | Intervention |
|-----------|--------|--------|--------------|
| Q3, 23/24 | 2.66   | 3      | 3.5          |
| Q4, 23/24 | 3.39   | 3      | 3.5          |

According to Table 38, over the period of the trial, there have been 1 quarter where the KPI target was not met but the KPI was not worse than the intervention level, and 1 quarter when the target was met.

- **Analysis 2 – Time series**

As can be seen in Figures 25 and 26, this KPI has only been met in 1 year for which data was available – 2020/21. Staff sickness has been above the target level in all other years.

Figure 25. Staff sickness days per FTE - SWS (non-cumulative) (monthly)





Figure 26. Staff sickness days per FTE - SWS (non-cumulative) (YoY)



**Table 39. Analysis 3 – Regression analysis**

| Variable   | Regression coefficient | 95% confidence interval |
|------------|------------------------|-------------------------|
| Intercept† | 3.98                   | 3.20, 4.75              |
| Quarter 2  | -0.05                  | -1.15, 1.05             |
| Quarter 3  | 0.26                   | -0.86, 1.37             |
| Quarter 4  | -0.10                  | -1.12, 1.02             |
| Trial      | -1.03                  | -2.69, 0.63             |

†Quarter 1 of the financial year, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis presented in Table 39 found no evidence of any statistically significant effects, either by quarter or from when the trial was started.

**Table 40. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable        | Regression coefficient | 95% confidence interval |
|-----------------|------------------------|-------------------------|
| Intercept†      | 4.07                   | 3.30, 4.84              |
| Quarter 2       | 0.04                   | -1.04, 1.13             |
| Quarter 3       | 0.27                   | -0.83, 1.37             |
| Quarter 4       | -0.08                  | -1.18, 1.01             |
| Trial           | -1.13                  | -2.77, 0.50             |
| COVID-19 period | -0.75                  | -1.81, 0.32             |

†Quarter 1 of the financial year, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis presented in Table 40 found no evidence of any statistically significant effects, either by quarter, during the COVID-19 period, or from when the trial was started.

## Planning service performance

### SX025: Average land charges search response days

Reported as non-cumulative monthly data, with lower values representing better performance.

**Table 41. Analysis 1 – KPI status**

| <b>KPIs</b>   | <b>Actual</b> | <b>Target</b> | <b>Intervention</b> |
|---------------|---------------|---------------|---------------------|
| <b>Jan-23</b> | 11.73         | 12            | 15                  |
| <b>Feb-23</b> | 9.31          | 12            | 15                  |
| <b>Mar-23</b> | 8.73          | 12            | 15                  |
| <b>Apr-23</b> | 10.29         | 10            | 12                  |
| <b>May-23</b> | 7.34          | 10            | 12                  |
| <b>Jun-23</b> | 10.59         | 10            | 12                  |
| <b>Jul-23</b> | 11.42         | 10            | 12                  |
| <b>Aug-23</b> | 11.29         | 10            | 12                  |
| <b>Sep-23</b> | 14.32         | 10            | 12                  |
| <b>Oct-23</b> | 8.50          | 10            | 12                  |
| <b>Nov-23</b> | 9.01          | 10            | 12                  |
| <b>Dec-23</b> | 7.66          | 10            | 12                  |
| <b>Jan-24</b> | 8.04          | 10            | 12                  |
| <b>Feb-24</b> | 4.41          | 10            | 12                  |
| <b>Mar-24</b> | 4.45          | 10            | 12                  |

Table 41 suggests that over the period of the trial, there has been 1 month (September 2023) where the KPI registered as worse than the intervention level, 4 months where the target was not met but the KPI was not worse than the intervention level, and 10 months where the target was met.

### **Analysis 2 – Time series**

As can be seen in Figures 27 and 28, there has been fluctuation in the performance on this outcome measure over time, with the worst performing years being 2016/17 and 2021/22.

Figure 27. Average land charges search response days (monthly)





Figure 28. Average land charges search response days (YoY)





**Table 42. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 8.85                   | 4.48, 13.22             |
| May                    | -0.05                  | -6.20, 6.10             |
| June                   | 1.12                   | -5.03, 7.27             |
| July                   | 1.46                   | -4.69, 7.61             |
| August                 | 2.19                   | -3.96, 8.34             |
| September              | 1.92                   | -4.23, 8.07             |
| October                | 1.19                   | -4.96, 7.34             |
| November               | -0.24                  | -6.39, 8.91             |
| December               | -0.59                  | -6.73, 5.56             |
| January                | -0.21                  | -6.37, 5.96             |
| February               | -0.92                  | -7.08, 5.25             |
| March                  | -1.09                  | -7.26, 5.07             |
| Trial                  | 0.12                   | -3.38, 3.61             |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

The analysis in Table 42 found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 43. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 7.83                   | 3.46, 12.21             |
| May                    | -0.05                  | -6.07, 5.97             |
| June                   | 1.12                   | -4.90, 7.14             |
| July                   | 1.46                   | -4.55, 7.48             |
| August                 | 2.66                   | -3.37, 8.69             |
| September              | 2.39                   | -3.64, 8.42             |
| October                | 1.65                   | -4.38, 7.68             |
| November               | 0.23                   | -5.80, 6.26             |
| December               | -0.12                  | -6.15, 5.91             |
| January                | 0.17                   | -5.87, 6.21             |
| February               | -0.54                  | -6.58, 5.50             |
| March                  | -0.72                  | -6.76, 5.32             |
| Trial                  | 0.83                   | -2.65, 4.31             |
| COVID-19 period        | 3.73                   | <b>0.33, 7.13*</b>      |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 43, the analysis found no evidence of any statistically significant effects by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation. However, there was a significant increase in response times during the COVID-19 period, compared to outside of it.

**Planning services measure: major planning application decisions (% completed in time)**


Reported as non-cumulative monthly data, with higher values representing better performance.


- **Analysis 1 – KPI status**

Not applicable as this outcome is not a KPI, and therefore there is no target threshold for it.

- **Analysis 2 – Time series**

As can be seen in Figures 29 and 30, there is considerably variation in the monthly outcomes, because of the relatively small numbers of decisions made per month. However, the yearly average shows a consistent outcome from 2020-23, with a considerable improvement in 2023/24.





**Table 44. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 58.22                  | 37.54, 78.90            |
| May                    | 1.11                   | -27.79, 30.01           |
| June                   | 7.03                   | -21.87, 35.93           |
| July                   | 18.89                  | -10.02, 47.78           |
| August                 | 16.05                  | -12.85, 44.95           |
| September              | 14.73                  | -14.17, 43.63           |
| October                | 11.53                  | -17.37, 40.42           |
| November               | 5.40                   | -23.50, 34.30           |
| December               | 0.67                   | -28.23, 29.57           |
| January                | 0.29                   | -27.19, 27.77           |
| February               | -4.79                  | -32.27, 22.70           |
| March                  | -1.07                  | -28.55, 26.41           |
| Trial                  | 15.47                  | <b>2.76, 28.17*</b>     |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
 \*Result is statistically significant at the 95% level

According to Table 44, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement in the trial period, compared to before the trial was introduced. Approximately 15% more major planning application decisions were completed within the correct timescale during the trial, compared to before.

**Table 45. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 48.14                  | 27.13, 69.14            |
| May                    | 1.11                   | -25.97, 28.19           |
| June                   | 7.03                   | -20.05, 34.11           |
| July                   | 18.88                  | -8.20, 45.96            |
| August                 | 20.20                  | -7.09, 47.48            |
| September              | 18.88                  | -8.41, 46.16            |
| October                | 15.67                  | -11.61, 42.96           |
| November               | 9.55                   | -17.74, 36.84           |
| December               | 4.82                   | -22.47, 32.10           |
| January                | 4.20                   | -21.75, 30.14           |
| February               | -0.88                  | -26.82, 25.07           |
| March                  | 2.84                   | -23.11, 28.78           |
| Trial                  | 22.60                  | <b>9.38, 35.81*</b>     |
| COVID-19 period        | 16.59                  | <b>3.25, 29.94*</b>     |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 45, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement both during the COVID-19 period and in the trial period, compared to outside those periods. Approximately 17% more major planning application decisions were completed within the correct timescale during the COVID-19 period, compared to outside it, and approximately 23% more major planning application decisions were completed within the correct timescale during the trial, compared to before.

#### **Planning services measure: major planning application decisions (% overturned)**

Reported as non-cumulative monthly data, with lower values representing better performance.

- **Analysis 1 – KPI status**

Not applicable as this outcome is not a KPI, and therefore there is no target threshold for it.

- **Analysis 2 – Time series**

As can be seen in Figures 31 and 32, proportions of major planning decisions overturned are consistently low, but are highest in 2021/22.

Figure 31. Major planning application decisions (% overturned)





Figure 32. Major planning application decisions (% overturned) - YoY



**Table 46. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 4.12                   | -1.71, 9.96             |
| May   | -3.57                  | -11.72, 4.57            |
| June  | -1.30                  | -9.45, 6.85             |
| July  | -1.30                  | -9.45, 6.85             |
| August  | 0.00                   | -8.15, 8.15             |
| September   | -3.57                  | -11.72, 4.58            |
| October   | 1.98                   | -6.17, 10.13            |
| November  | 2.06                   | -6.09, 10.21            |
| December  | -3.57                  | -11.72, 4.58            |
| January   | -1.02                  | -8.77, 6.73             |
| February  | -3.24                  | -10.99, 4.51            |
| March   | 0.09                   | -7.66, 7.84             |
| Trial   | -2.21                  | -5.79, 1.37             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 46, the analysis found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 47. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 6.49                   | 0.41, 12.57             |
| May  | -3.57                  | -11.41, 4.26            |
| June   | -1.30                  | -9.13, 6.64             |
| July   | -1.30                  | -9.13, 6.64             |
| August   | -0.97                  | -8.87, 6.92             |
| September  | -4.55                  | -12.44, 3.35            |
| October  | 1.01                   | -6.89, 8.90             |
| November   | 1.09                   | -6.81, 8.98             |
| December   | -4.55                  | -12.44, 3.35            |
| January  | -1.94                  | -9.44, 5.57             |
| February   | -4.16                  | -11.66, 3.35            |
| March  | -0.82                  | -8.33, 6.68             |
| Trial  | -3.89                  | <b>-7.71, -0.06*</b>    |
| COVID-19 period  | -3.90                  | <b>-7.76, -0.04*</b>    |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As can be seen in Table 47, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement both during the COVID-19 period and in the trial period, compared to outside those periods. Approximately 4% fewer major planning application decisions were overturned during the COVID-19 period, compared to outside it, and approximately 4% fewer major planning application decisions were overturned during the trial, compared to before.

**Planning services measure: non-major planning application decisions (% completed in time)**


Reported as non-cumulative monthly data, with higher values representing better performance.


- **Analysis 1 – KPI status**

Not applicable as this outcome is not a KPI, and therefore there is no target threshold for it.

- **Analysis 2 – Time series**

As can be seen in Figures 33 and 34, the higher number of non-major planning applications (compared to major planning applications) means there is less monthly volatility in the outcomes, with a fairly consistent percentage being completed on time across different years.





**Table 48. Analysis 3 – Regression analysis**

| Variable   | Regression coefficient | 95% confidence interval |
|------------|------------------------|-------------------------|
| Intercept† | 70.38                  | 62.60, 78.16            |
| May        | -2.58                  | -13.44, 8.29            |
| June       | 6.10                   | -4.77, 16.97            |
| July       | 4.70                   | -6.17, 15.56            |
| August     | 6.57                   | -4.30, 17.44            |
| September  | 0.42                   | -10.45, 11.28           |
| October    | 1.50                   | -9.37, 12.36            |
| November   | 4.99                   | -5.88, 15.85            |
| December   | 5.50                   | -5.37, 16.37            |
| January    | 0.41                   | -9.92, 10.75            |
| February   | -4.17                  | -14.50, 6.17            |
| March      | -2.49                  | -12.82, 7.85            |
| Trial      | 13.05                  | <b>8.27, 17.82*</b>     |

†April, outside of the trial period, is used as the reference category in the analysis  
 \*Result is statistically significant at the 95% level

According to Table 48, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement in the trial period, compared to before the trial was introduced. Approximately 13% more non-major planning application decisions were completed within the correct timescale during the trial, compared to before.



**Table 49. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 65.25                  | 57.93, 72.56            |
| May                    | -2.58                  | -12.00, 6.85            |
| June                   | 6.10                   | -3.33, 15.53            |
| July                   | 4.70                   | -4.73, 14.12            |
| August                 | 8.68                   | -0.82, 18.18            |
| September              | 2.53                   | -6.97, 12.03            |
| October                | 3.61                   | -5.89, 13.11            |
| November               | 7.10                   | -2.40, 16.60            |
| December               | 7.61                   | -1.89, 17.11            |
| January                | 2.40                   | -6.63, 11.43            |
| February               | -2.18                  | -11.21, 6.85            |
| March                  | -0.50                  | -9.53, 8.53             |
| Trial                  | 16.68                  | <b>12.08, 21.28*</b>    |
| COVID-19 period        | 8.45                   | <b>3.80, 13.09*</b>     |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 49, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement both during the COVID-19 period and in the trial period, compared to outside those periods. Approximately 8% more non-major planning application decisions were completed within the correct timescale during the COVID-19 period, compared to outside it, and approximately 17% more non-major planning application decisions were completed within the correct timescale during the trial, compared to before.

#### **Planning services measure: non-major planning application decisions (% overturned)**

Reported as non-cumulative monthly data, with lower values representing better performance.

- **Analysis 1 – KPI status**

Not applicable as this outcome is not a KPI, and therefore there is no target threshold for it.

- **Analysis 2 – Time series**

As can be seen in Figures 35 and 36, there has been fluctuation in the performance on this outcome measure over time, with the best performing year being 2023/24.

Figure 35. Non-major planning application decisions (% overturned)





Figure 36. Non-major planning application decisions (% overturned) - YoY



**Table 50. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 0.65                   | 0.00, 1.30              |
| May   | 0.35                   | -0.56, 1.26             |
| June  | 0.07                   | -0.84, 0.98             |
| July  | -0.04                  | -0.95, 0.87             |
| August  | -0.12                  | -1.03, 0.78             |
| September   | -0.34                  | -1.25, 0.56             |
| October   | 0.25                   | 0.25, 1.16              |
| November  | 0.27                   | -0.64, 1.18             |
| December  | 0.08                   | -0.83, 0.99             |
| January   | 0.48                   | -0.39, 1.34             |
| February  | 0.30                   | -0.56, 1.17             |
| March   | 0.04                   | -0.82, 0.91             |
| Trial   | -0.51                  | <b>-0.91, -0.11*</b>    |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 50, the analysis found no evidence of any statistically significant effects by month, but there was statistically significant evidence of a small reduction in the % of non-major planning application decisions that were overturned during the trial period, compared to before the trial.

**Table 51. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 0.75                   | 0.03, 1.46              |
| May  | 0.35                   | -0.57, 1.26             |
| June   | 0.07                   | -0.85, 0.98             |
| July   | -0.04                  | -0.96, 0.78             |
| August   | -0.16                  | -1.09, 0.76             |
| September  | -0.38                  | -1.31, 0.54             |
| October  | 0.21                   | -0.71, 1.14             |
| November   | 0.23                   | -0.69, 1.16             |
| December   | 0.05                   | -0.88, 0.97             |
| January  | 0.44                   | -0.44, 1.32             |
| February   | 0.27                   | -0.61, 1.15             |
| March  | 0.00                   | -0.87, 0.88             |
| Trial  | -0.58                  | <b>-1.02, -0.13*</b>    |
| COVID-19 period  | -0.15                  | -0.61, 0.30             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As can be seen in Table 51, the analysis found no evidence of any statistically significant effects by month or during the COVID-19 period, but there was statistically significant evidence of a small reduction in the % of non-major planning application decisions that were overturned during the trial period, compared to before the trial.

**Planning services measure: average number of weeks for householder planning application determination**


Reported as non-cumulative monthly data, with lower values representing better performance.


- **Analysis 1 – KPI status**

Not applicable as this outcome is not a KPI, and therefore there is no target threshold for it.

- **Analysis 2 – Time series**

As can be seen in Figures 37 and 38, the best performing years on this measure were 2018/19 and 2023/24.





**Table 52. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 11.19                  | 9.67, 12.70             |
| May                    | 0.93                   | -1.20, 3.06             |
| June                   | 0.68                   | -1.45, 2.81             |
| July                   | 0.26                   | -1.86, 2.39             |
| August                 | 1.12                   | -1.01, 3.25             |
| September              | 0.65                   | -1.48, 2.78             |
| October                | 0.71                   | -1.42, 2.84             |
| November               | -0.34                  | -2.47, 1.79             |
| December               | 1.15                   | -0.98, 3.27             |
| January                | -0.26                  | -2.40, 1.88             |
| February               | 1.20                   | -0.94, 3.33             |
| March                  | 0.68                   | -1.45, 2.82             |
| Trial                  | -1.87                  | <b>-2.96, -0.78*</b>    |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

According to Table 52, the analysis found no evidence of any statistically significant effects by month, but there was statistically significant evidence of a reduction of approximately 1.9 weeks in the average number of weeks for householder planning application determination during the trial period, compared to before the trial.

**Table 53. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 10.67                  | 9.17, 12.17             |
| May                    | 0.93                   | -1.10, 2.97             |
| June                   | 0.68                   | -1.35, 2.71             |
| July                   | 0.26                   | -1.77, 2.30             |
| August                 | 1.35                   | -0.69, 3.39             |
| September              | 0.88                   | -1.16, 2.92             |
| October                | 0.94                   | -1.10, 2.98             |
| November               | -0.12                  | -2.16, 1.93             |
| December               | 1.37                   | -0.67, 3.41             |
| January                | -0.10                  | -2.14, 1.95             |
| February               | 1.36                   | -0.68, 3.41             |
| March                  | 0.85                   | -1.20, 2.89             |
| Trial                  | -1.49                  | <b>-2.57, -0.41*</b>    |
| COVID-19 period        | 1.37                   | <b>0.31, 2.42*</b>      |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 53, the analysis found no evidence of any statistically significant effects by month, but there was statistically significant evidence of an increase of approximately 1.4 weeks in the average number of weeks for householder planning application determination during the COVID-19 period, compared to outside that period, and a reduction of approximately 1.5 weeks in the average number of weeks for householder planning application determination during the trial period, compared to before the trial.

## Housing services performance

### AH204: % tenant satisfaction with responsive repairs

Reported as non-cumulative quarterly data, with higher values representing better performance.



**Table 54. Analysis 1 – KPI status**

| KPIs      | Actual | Target | Intervention |
|-----------|--------|--------|--------------|
| Q4, 22/23 | 92     | 97     | 92           |
| Q1, 23/24 | 96     | 97     | 92           |
| Q2, 23/24 | 93     | 97     | 92           |
| Q3, 23/24 | 93     | 97     | 92           |
| Q4, 23/24 | 91     | 97     | 92           |

According to Table 54, over the period of the trial, there has been 1 quarter (January-March 2024) where the KPI registered as worse than the intervention level, and 4 quarters where the target was not met but the KPI was not worse than the intervention level.

- **Analysis 2 – Time series**

As can be seen in Figures 39 and 40, this KPI fell below the target in 2020/21, and has still not recovered to the target level.



**Table 55. Analysis 3 – Regression analysis**

| <b>Variable</b>        | <b>Regression coefficient</b> | <b>95% confidence interval</b> |
|------------------------|-------------------------------|--------------------------------|
| Intercept <sup>†</sup> | 95.43                         | 91.62, 99.24                   |
| Quarter 2              | -2.42                         | -7.73, 2.89                    |
| Quarter 3              | -2.81                         | -8.11, 2.50                    |
| Quarter 4              | -1.48                         | -6.83, 3.87                    |
| Trial                  | -0.74                         | -5.96, 4.49                    |

†Quarter 1 of the financial year, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 55, the analysis found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 56. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| <b>• Variable</b>      | <b>Regression coefficient</b> | <b>95% confidence interval</b> |
|------------------------|-------------------------------|--------------------------------|
| Intercept <sup>†</sup> | 96.91                         | 94.27, 99.55                   |
| Quarter 2              | -1.16                         | -4.80, 2.47                    |
| Quarter 3              | -2.81                         | -6.41, 0.80                    |
| Quarter 4              | -1.25                         | -4.89, 2.39                    |
| Trial                  | -2.56                         | -6.17, 1.05                    |
| COVID-19 period        | -10.04                        | -13.66, -6.43                  |

†Quarter 1 of the financial year, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

According to Table 56, the analysis found no evidence of any statistically significant effects by quarter or from when the trial was started. However, there was a significant decrease in tenant satisfaction with responsive repairs during the COVID-19 period, compared to outside of it.



## AH211: Average days to re-let all housing stock

Reported as non-cumulative monthly data, with lower values representing better performance.

**Table 57. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 25     | 17     | 25           |
| Feb-23 | 27     | 17     | 25           |
| Mar-23 | 25     | 17     | 25           |
| Apr-23 | 38     | 17     | 25           |
| May-23 | 33     | 17     | 25           |
| Jun-23 | 22     | 17     | 25           |
| Jul-23 | 30     | 17     | 25           |
| Aug-23 | 26     | 17     | 25           |
| Sep-23 | 29     | 17     | 25           |
| Oct-23 | 24     | 17     | 25           |
| Nov-23 | 39     | 17     | 25           |
| Dec-23 | 30     | 17     | 25           |
| Jan-24 | 30     | 17     | 25           |
| Feb-24 | 33     | 17     | 25           |
| Mar-24 | 30     | 17     | 25           |

As can be seen in Table 57, over the period of the trial, there have been 11 months where the KPI registered as worse than the intervention level, and 4 months where the target was not met but the KPI was not worse than the intervention level.

- **Analysis 2 – Time series**

As can be seen in Figure 41 and 42, this KPI rose to considerably above the target in 2020/21 and has still not recovered to the target level.

Figure 41. Average days to re-let all housing stock (monthly)





Figure 42. Average days to re-let all housing stock (YoY)



**Table 58. Analysis 3 – Regression analysis**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 30.50                  | 15.75, 45.25            |
| May                    | 4.00                   | -16.76, 24.76           |
| June                   | 4.56                   | -16.20, 25.32           |
| July                   | 0.19                   | -20.57, 20.95           |
| August                 | 0.75                   | -20.01, 21.51           |
| September              | 3.13                   | -17.63, 23.88           |
| October                | -4.00                  | -24.76, 16.76           |
| November               | -3.19                  | -23.95, 17.57           |
| December               | -2.88                  | -23.63, 17.88           |
| January                | 2.88                   | -17.94, 23.69           |
| February               | -1.62                  | -22.44, 19.19           |
| March                  | -3.25                  | -24.06, 17.56           |
| Trial                  | -1.01                  | -12.81, 10.80           |

<sup>†</sup>April, outside of the trial period, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

According to Table 58, the analysis found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 59. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable               | Regression coefficient | 95% confidence interval |
|------------------------|------------------------|-------------------------|
| Intercept <sup>†</sup> | 18.71                  | 9.62, 27.80             |
| May                    | 4.00                   | -8.50, 16.50            |
| June                   | 4.56                   | -7.94, 17.06            |
| July                   | 0.19                   | -12.31, 12.69           |
| August                 | 6.13                   | -6.40, 18.66            |
| September              | 8.50                   | -4.03, 21.03            |
| October                | 1.38                   | -11.15, 13.91           |
| November               | 2.19                   | -10.34, 14.72           |
| December               | 2.50                   | -10.03, 15.03           |
| January                | 7.22                   | -5.33, 19.77            |
| February               | 2.72                   | -9.83, 15.27            |
| March                  | 1.10                   | -11.45, 13.65           |
| Trial                  | 7.25                   | <b>0.02, 14.49*</b>     |
| COVID-19 period        | 43.02                  | <b>35.96, 50.08*</b>    |

<sup>†</sup>April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis  
\*Result is statistically significant at the 95% level

As can be seen in Table 59, the analysis found no evidence of any statistically significant effects by month of the year. There is evidence that both the trial and COVID-19 periods were worse than the long-term average, with the average number of days to relet housing stock increasing by 43.0 days during the COVID-19 period, compared to the long-term average, increased by 7.3 days during the trial period, compared to the long-term average.

**SH332: % of emergency housing repairs in 24 hours**

Reported as non-cumulative monthly data, with higher values representing better performance.

**Table 60. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Jan-23 | 100    | 100    | 98           |
| Feb-23 | 100    | 100    | 98           |
| Mar-23 | 100    | 100    | 98           |
| Apr-23 | 100    | 100    | 98           |
| May-23 | 100    | 100    | 98           |
| Jun-23 | 100    | 100    | 98           |
| Jul-23 | 100    | 100    | 98           |
| Aug-23 | 100    | 100    | 98           |
| Sep-23 | 100    | 100    | 98           |
| Oct-23 | 100    | 100    | 98           |
| Nov-23 | 100    | 100    | 98           |
| Dec-23 | 100    | 100    | 98           |
| Jan-24 | 100    | 100    | 98           |
| Feb-24 | 100    | 100    | 98           |
| Mar-24 | 100    | 100    | 98           |

According to Table 60, over the period of the trial, the KPI was met for all months.

- **Analysis 2 – Time series**

As can be seen in Figures 43 and 44, there was fluctuation in the performance on this outcome measure between 2016 and 2021, but from 2022-24 the KPI has been consistently met.

Figure 43. % of emergency repairs in 24 hours (monthly)





Figure 44. % of emergency repairs in 24 hours (YoY)



**Table 61. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 97.56                  | 95.77, 99.35            |
| May   | -0.04                  | -2.56, 2.47             |
| June  | -0.78                  | -3.29, 1.74             |
| July  | -2.07                  | -4.58, 0.45             |
| August  | 0.11                   | -2.41, 2.63             |
| September   | -0.56                  | -3.08, 1.95             |
| October   | -1.76                  | -4.28, 0.76             |
| November  | -0.17                  | -2.68, 2.35             |
| December  | -0.73                  | -3.24, 1.79             |
| January   | -0.40                  | -2.93, 2.12             |
| February  | -0.19                  | -2.71, 2.34             |
| March   | -0.09                  | -2.61, 2.44             |
| Trial   | 2.93                   | <b>1.50, 4.36*</b>      |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As can be seen in Table 61, the analysis found no evidence of any statistically significant effects by month of the year but did find a significant improvement in the trial period, compared to before the trial was introduced. Approximately 2.9% more emergency repairs were completed within 24 hours during the trial, compared to before.

**Table 62. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 97.89                  | 96.08, 99.70            |
| May  | -0.04                  | -2.53, 2.45             |
| June   | -0.78                  | -3.26, 1.71             |
| July   | -2.07                  | -4.56, 0.42             |
| August   | -0.04                  | -2.54, 2.45             |
| September  | -0.71                  | -3.21, 1.78             |
| October  | -1.91                  | -4.40, 0.58             |
| November   | -0.32                  | -2.81, 2.18             |
| December   | -0.88                  | -3.37, 1.62             |
| January  | -0.52                  | -3.02, 1.97             |
| February   | -0.31                  | -2.81, 2.19             |
| March  | -0.21                  | -2.71, 2.29             |
| Trial  | 2.70                   | <b>1.26, 4.14*</b>      |
| COVID-19 period  | -1.21                  | -2.62, 0.19             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 62, the analysis found no evidence of any statistically significant effects by month of the year or during the COVID-19 period but did find a significant improvement in the trial period, compared to before the trial was introduced. Approximately 2.7% more emergency repairs were completed within 24 hours during the trial, compared to before.

## Waste management performance

### ES408: % bins collected on schedule

Reported as non-cumulative monthly data, with higher values representing better performance.



**Table 63. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Sep-23 | 99.79  | 99.7   | 99.25        |
| Oct-23 | 99.72  | 99.7   | 99.25        |
| Nov-23 | 99.79  | 99.7   | 99.25        |
| Dec-23 | 99.81  | 99.7   | 99.25        |
| Jan-24 | 99.69  | 99.7   | 99.25        |
| Feb-24 | 99.89  | 99.7   | 99.25        |
| Mar-24 | 99.86  | 99.7   | 99.25        |

As can be seen in Table 63, over the period of the trial, there has been 1 month (January 2024) where the KPI target was not met but the KPI was not worse than the intervention level, and 6 months when the target was met.

- **Analysis 2 – Time series**

As can be seen in Figures 45 and 46, from 2017 onwards, the outcome has been consistently above the target level over time.





**Table 64. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 99.62                  | 99.34, 99.90            |
| May   | 0.07                   | -0.33, 0.46             |
| June  | -0.01                  | -0.41, 0.38             |
| July  | 0.13                   | -0.26, 0.52             |
| August  | 0.14                   | -0.26, 0.53             |
| September   | 0.15                   | -0.24, 0.55             |
| October   | 0.13                   | -0.27, 0.52             |
| November  | 0.13                   | -0.26, 0.53             |
| December  | 0.19                   | -0.21, 0.59             |
| January   | 0.11                   | -0.28, 0.51             |
| February  | 0.18                   | -0.21, 0.58             |
| March   | -0.21                  | -0.60, 0.19             |
| Trial   | 0.08                   | -0.24, 0.40             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 64, the analysis found no evidence of any statistically significant effects, either by month or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**Table 65. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 99.58                  | 99.29, 99.86            |
| May  | 0.07                   | -0.32, 0.46             |
| June   | -0.01                  | -0.41, 0.38             |
| July   | 0.13                   | -0.26, 0.52             |
| August   | 0.15                   | -0.24, 0.55             |
| September  | 0.17                   | -0.22, 0.57             |
| October  | 0.14                   | -0.25, 0.54             |
| November   | 0.15                   | -0.25, 0.54             |
| December   | 0.21                   | -0.19, 0.60             |
| January  | 0.13                   | -0.26, 0.53             |
| February   | 0.20                   | -0.19, 0.60             |
| March  | -0.19                  | -0.59, 0.20             |
| Trial  | 0.10                   | -0.22, 0.42             |
| COVID-19 period  | 0.16                   | -0.06, 0.38             |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As can be seen in Table 65, the analysis found no evidence of any statistically significant effects, either by month, during the COVID-19 period, or from when the trial was started. The impact of the introduction of the trial appears to be minimal, and smaller than the level of month-by-month variation.

**ES418: % of household waste sent for reuse, recycling and composting**

Reported as cumulative data, based on the proportion sent from the start of the relevant financial year up to the point of measurement, with higher values representing better performance.

**Table 66. Analysis 1 – KPI status**

| KPIs   | Actual | Target | Intervention |
|--------|--------|--------|--------------|
| Sep-23 | 53.68  | 52     | 48           |
| Oct-23 | 52.78  | 52     | 48           |
| Nov-23 | 52.38  | 52     | 48           |
| Dec-23 | 51.76  | 52     | 48           |
| Jan-24 | 50.73  | 52     | 48           |
| Feb-24 | 49.98  | 52     | 48           |
| Mar-24 | 49.91  | 52     | 48           |

According to Table 66, over the period of the trial, there has been 4 months (December 2023-March 2024) where the KPI target was not met but the intervention level was not reached, and 3 months where the target was met.

- **Analysis 2 – Time series**

As can be seen in Figures 47 and 48, there has been fluctuation in the performance on this outcome measure over time, with the worst performing year being 2022/23.

Data for this KPI are not available for January or February 2017.

Figure 47: % of household waste sent for reuse, recycling and composting (monthly)





Figure 48: % of household waste sent for reuse, recycling and composting (YoY - data for September-March)



**Table 67. Analysis 3 – Regression analysis**

| Variable  | Regression coefficient | 95% confidence interval |
|---|------------------------|-------------------------|
| Intercept <sup>†</sup>  | 49.82                  | 48.14, 51.50            |
| May   | 3.12                   | <b>0.74, 5.50*</b>      |
| June  | 3.87                   | <b>1.49, 6.24*</b>      |
| July  | 3.40                   | <b>1.02, 5.78*</b>      |
| August  | 3.43                   | <b>1.05, 5.81*</b>      |
| September   | 3.43                   | <b>1.04, 5.82*</b>      |
| October   | 3.09                   | <b>0.69, 5.48*</b>      |
| November  | 2.89                   | <b>0.49, 5.28*</b>      |
| December  | 1.88                   | -0.51, 4.28             |
| January   | 1.15                   | -1.33, 3.63             |
| February  | 0.54                   | -1.94, 3.02             |
| March   | 0.73                   | -1.66, 3.13             |
| Trial   | -0.16                  | -2.09, 1.77             |
| <sup>†</sup> April, outside of the trial period, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

As can be seen in Table 67, the analysis found seven significant results, which are that outcomes from May-November appear to be better than the reference category (April). There is no evidence of a statistically significant impact from the introduction of the trial.

**Table 68. Analysis 4 – Regression analysis, adjusting for the impact of COVID-19**

| Variable   | Regression coefficient | 95% confidence interval |
|--|------------------------|-------------------------|
| Intercept <sup>†</sup>   | 50.28                  | 48.64, 51.93            |
| May  | 3.12                   | <b>0.84, 5.40*</b>      |
| June   | 3.87                   | <b>1.59, 6.14*</b>      |
| July   | 3.40                   | <b>1.13, 5.68*</b>      |
| August   | 3.20                   | <b>0.91, 5.48*</b>      |
| September  | 3.23                   | <b>0.94, 5.52*</b>      |
| October  | 2.89                   | <b>0.59, 5.18*</b>      |
| November   | 2.69                   | <b>0.39, 4.98*</b>      |
| December   | 1.69                   | -0.61, 3.98             |
| January  | 0.99                   | -1.38, 3.37             |
| February   | 0.38                   | -1.99, 2.76             |
| March  | 0.54                   | -1.76, 2.83             |
| Trial  | -0.44                  | -2.30, 1.42             |
| COVID-19 period  | -1.86                  | <b>-3.13, -0.59*</b>    |
| <sup>†</sup> April, outside of both the COVID-19 and trial periods, is used as the reference category in the analysis<br>*Result is statistically significant at the 95% level |                        |                         |

According to Table 68, the analysis found eight significant results, which are that outcomes from May-November appear to be better than the reference category (April), and the outcomes during the COVID-19 period are worse than the outcomes outside that period. There is no evidence of a statistically significant impact from the introduction of the trial.